William J Watson1. 1. Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota 55905, USA. Watson.William@mayo.edu
Abstract
BACKGROUND: Herceptin (trastuzumab), a new a chemotherapeutic agent, is a monoclonal antibody that blocks the human epidermal growth factor receptor 2 protein. There is no reported experience with use of this agent during pregnancy and possible effects on the fetus. CASE: A patient with breast cancer was treated with Herceptin during pregnancy. This treatment was associated with anhydramnios, which resolved slowly after the drug was discontinued. CONCLUSION: Although listed as a category B drug, experience with Herceptin in human pregnancy is limited, and it should be used with caution. Investigation of the role of human epidermal growth factor receptor 2 protein in the embryonic kidney may further our understanding of amniotic fluid dynamics.
BACKGROUND:Herceptin (trastuzumab), a new a chemotherapeutic agent, is a monoclonal antibody that blocks the humanepidermal growth factor receptor 2 protein. There is no reported experience with use of this agent during pregnancy and possible effects on the fetus. CASE: A patient with breast cancer was treated with Herceptin during pregnancy. This treatment was associated with anhydramnios, which resolved slowly after the drug was discontinued. CONCLUSION: Although listed as a category B drug, experience with Herceptin in human pregnancy is limited, and it should be used with caution. Investigation of the role of humanepidermal growth factor receptor 2 protein in the embryonic kidney may further our understanding of amniotic fluid dynamics.
Authors: Matthew J Goodyer; Jeffri Rm Ismail; Seamus P O'Reilly; Eugene J Moylan; C Anthony M Ryan; Paul Af Hughes; Alan O'Connor Journal: Cases J Date: 2009-12-16
Authors: Ingo Gottschalk; Christoph Berg; Nadia Harbeck; Rüdiger Stressig; Peter Kozlowski Journal: Breast Care (Basel) Date: 2011-12-16 Impact factor: 2.860